What were the biggest takeaways from ESMO 2023 related to TNBC and IBC? Tune in to hear experts Drs Kevin Kalinsky and Filipa Lynce discuss.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Inflammatory Breast Cancer: What You Should Know https://www.medscape.com/viewarticle/778334

Incidence, Characteristics, and Management of Central Nervous System Metastases in Patients With Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36210737/

Inflammatory Breast Cancer Cells Are Characterized by Abrogated Tgfβ1-Dependent Cell Motility and SMAD3 Activity https://pubmed.ncbi.nlm.nih.gov/32043194/

JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States https://pubmed.ncbi.nlm.nih.gov/36409824/

Whole-Genome Sequencing of Phenotypically Distinct Inflammatory Breast Cancers Reveals Similar Genomic Alterations to Non-inflammatory Breast Cancers https://pubmed.ncbi.nlm.nih.gov/33902690/

OncoPanel http://cancergeneticslab.ca/genes/oncopanel/

TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI) https://classic.clinicaltrials.gov/ct2/show/NCT05795101

Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer: Results From the NeoSTAR Trial https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.512

The I-SPY Trials https://www.ispytrials.org/

381O First-in-Human/Phase I Trial of HS-20089, a B7-H4 ADC, in Patients With Advanced Solid Tumors https://www.annalsofoncology.org/article/S0923-7534(23)01394-7/fulltext

660MO - First-in-Human Study of SGN-B7H4V, a B7-H4-Directed Vedotin ADC, in Patients With Advanced Solid Tumors: Preliminary Results of a Phase I Study (SGNB7H4V-001) https://oncologypro.esmo.org/meeting-resources/esmo-congress/first-in-human-study-of-sgn-b7h4v-a-b7-h4-directed-vedotin-adc-in-patients-with-advanced-solid-tumors-preliminary-results-of-a-phase-i-study-sg

The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma https://pubmed.ncbi.nlm.nih.gov/37871703/

Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/

BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/

Iniparib Plus Chemotherapy in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/21208101/

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant https://pubmed.ncbi.nlm.nih.gov/31461380/

ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542

Pathological Complete Response in Neoadjuvant Treatment of High-risk Early-stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry https://www.fda.gov/media/83507/download

Adjuvant Olaparib for Patients With BRCA1- or BRCA2-mutated Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34081848/

PALB2 Partner and Localizer of BRCA2 https://www.ncbi.nlm.nih.gov/gene/79728

Pre-specified Event Driven Analysis of Overall Survival (OS) in the OlympiA Phase III Trial of Adjuvant Olaparib (OL) in Germline BRCA1/2 Mutation (gBRCAm) Associated Breast Cancer https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/olympia-phase-iii-pre-specified-event-driven-analysis-of-overall-survival-of-olaparib-in-gbrcam-breast-cancer

Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/

Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/28578601/

Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/30110579/

Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study https://pubmed.ncbi.nlm.nih.gov/29045554/

RAD51 Recombinase https://www.ncbi.nlm.nih.gov/gene/5888

The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/34068084/

Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq

Tissue-agnostic Drug Approvals: How Does This Apply to Patients With Breast Cancer? https://pubmed.ncbi.nlm.nih.gov/34518552/

What does the cutting edge of radiation oncology look like for treating triple-negative breast cancer? Tune in to hear experts Drs Kevin Kalinsky and Reshma Jagsi discuss.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

A Review of the Abscopal Effect in the Era of Immunotherapy https://pubmed.ncbi.nlm.nih.gov/36321062/

The Impact of Radiation-induced DNA Damage on cGAS-STING-mediated Immune Responses to Cancer https://pubmed.ncbi.nlm.nih.gov/33238631/

Gray (Gy) https://www.nrc.gov/reading-rm/basic-ref/glossary/gray-gy.html

Event-free Survival With Pembrolizumab in Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35139274/

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer https://clinicaltrials.gov/study/NCT02954874

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) https://clinicaltrials.gov/study/NCT04443348

Translational Breast Cancer Research Consortium (TBCRC) https://tbcrc.org/

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/34900718/

SWOG Cancer Research Network https://www.swog.org/

BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study https://pubmed.ncbi.nlm.nih.gov/29558281/

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer https://clinicaltrials.gov/study/NCT03598257

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542

Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-stage Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32613290/

Regional Radiotherapy in Biomarker Low-risk Node Positive and T3N0 Breast Cancer (TAILOR RT) https://classic.clinicaltrials.gov/ct2/show/NCT03488693

Postoperative Radiotherapy in High-risk Premenopausal Women With Breast Cancer Who Receive Adjuvant Chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial https://pubmed.ncbi.nlm.nih.gov/9395428/

Postoperative Radiotherapy in High-risk Postmenopausal Breast-cancer Patients Given Adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10335782/

Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/23484825/

Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-risk, Node-positive Breast Cancer Enrolled in the SWOG S1007 Trial https://pubmed.ncbi.nlm.nih.gov/37410451/